

ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司)

(Stock Code 股份代號: 6855)

16 April 2024

Dear Non-registered Shareholder,

Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to the amended Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") effective from 31 December 2023, the Company has adopted new arrangement to disseminate corporate communications ("Corporate Communications") electronically. No printed copies of Corporate Communications will be mailed out to you except by request. Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at Ascentage.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk (the "Website Version") in place of printed copies.

The Company will not send a notice of publication of the website version of Corporate Communications to you. The Shareholders are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Website Version of Corporate Communications by yourselves.

We encourage you to access Corporate Communications of the Company in electronic form on the Company's website. If you wish to receive hard copies of all future Corporate Communications, please complete and return the Request Form on the reverse side of this letter to the Company's branch share registrar in Hong Kong (the "Share Registrar"), Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or send an email to 6855-ecom@hk.tricorglobal.com. Please note that the hardcopy request will be valid until expiry on 31 December 2024 unless being revoked or superseded (whichever is earlier). Further request in writing will be required if a non-registered shareholder prefers to continue receiving hard copies of future Corporate Communications.

Should you have any queries relating to any of the above matters, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 5:00 p.m. Monday to Friday, excluding public holidays or send an email to 6855-ecom@hk.tricorglobal.com.

By the order of the Board

Ascentage Pharma Group International

Dr. Yang Dajun

Chairman and Executive Director

Note:

Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the environmental, social and governance report; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.

各位非登記股東:

以電子方式發布公司通訊之安排

根據已於2023年12月31日生效的經修訂香港聯合交易所有限公司(「聯交所」)證券上市規則(「上市規則」),本公司採納有關向其非登記股東發佈日後所有公司通訊的新安排。所有公司通訊均透過本公司網站(ascentage.cn)及聯交所網站(www.hkexnews.hk)(「網站版本」)以電子方式向非登記股東提供並僅會於個別非登記股東要求時才向其發送印刷本。 閣下可於本公司網站(ascentage.cn)及聯交所網站(www.hkexnews.hk)瀏覽本公司的中、英文版本公司通訊的網站版本。

我們不會向 閣下發出公司通訊網站版本的登載通知。本公司鼓勵 閣下主動留意網站上所有日後的公司通訊的登載情况,並自行瀏覽公司通訊的網站版本。

我們鼓勵 閣下於本公司網站以電子形式瀏覽本公司的公司通訊。若閣下希望收取日後公司通訊之印刷版,請填妥本函背頁之申請表格並交回本公司的香港股份過戶登記分處(「股份過戶登記處」)卓佳證券登記有限公司,地址為香港夏粮道16號遠東金融中心17樓或發送電子郵件至6855-ecom@hk.tricorglobal.com。請注意,非登記股東的印刷版本要求將直至2024年12月31日到期前有效,除非被撤銷或取代(以較早者為準)。若非登記股東希望繼續收到日後公司通訊的印刷本,則需要再作書面要求。

如 閣下對本函內容有任何疑問,請致電本公司股份過戶登記處電話熱線(852) 2980 1333,辦公時間為星期一至五(公眾假期除外)上午9時正至下午5時正,或 電郵至6855-ecom@hk.tricorglobal.com。

承董事會命

亞盛醫藥集團 主席兼執行董事

楊大俊博士

2024年4月16日

附註: 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告, 公司年度帳目連同核數師報告以及(如適用)財務摘要報告;(b)中期報告及(如適用)中期摘要報告;(c)環境、社會及管治報告;(d)會 議通告;(e)上市文件;(f)通函;及(g)代表委任表格。

REQUEST FORM 申請表格

Ascentage Pharma Group International (Stock Code: 6855) (the "Company") c/o Tricor Investor Services Limited 17/F, Far East Finance Centre 16 Harcourt Road, Hong Kong

亞盛醫藥集團 (股份代號: 6855)(「本公司」)

> 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓

REMINDER 提示

As a non-registered shareholder, if you wish to receive Corporate Communications (1) pursuant to the Listing Rules, you should liaise with your bank(s), broker(s), custodian(s), nominee(s) or HKSCC Nominees Limited through which your shares are held (collectively, the "Intermediaries") and provide your email address to your Intermediaries.

作為非登記股東,如有意根據《上市規則》收取公司通訊(1) , 閣下應聯絡閣下持有股份的銀行、經紀、託管商、代理人或香港中央結算(代理人)有限公 司(統稱「中介公司」),並向閣下的中介公司提供閣下的電子郵件地址。

I/We would like to receive the current and future Corporate Communications(1) in printed copy of the Company. 本人/吾等要求索取本公司本次及今後刊發之公司通訊(1)之印刷本。

Signature: Date: 簽署: 日期:	
Name: Contact Phone Number: 姓名: (English英文) 聯絡電話:	
(in block letters 請以正楷填寫)	
Postal Address:	
郵寄地址:	

Notes 附註:

- "Corporate Communications" refer to any document issued or to be issued by the Company for the information or action of holders of any of the Company's securities, including but not limited to: (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the environmental, social and governance report; (d) a notice of meeting; (e) a listing document; and (f) a circular.
 - 「公司通訊」指由本公司發出或將予發出以供本公司任何證券的持有人參照或採取行動的任何文件,其中包括但不限於:(a)董事會報告、年度賬目連同核數師報告 及財務摘要報告(如適用);(b)中期報告及中期摘要報告(如適用);(c)環境、社會及管治報告;(d)會議通告;(e)上市文件;及(f)通函。
- By completing and returning this Request Form to request for the printed copy of the Current Corporate Communications, you have expressly indicated that you prefer 2 to receive all future Corporate Communications of the Company in printed copy. 當 閣下填寫及寄回此申請表格以索取刊發之本次公司通訊印刷本後,即表示 閣下確認擬收取本公司日後刊發的所有公司通訊的印刷本。
- This request will be valid unless being revoked or superseded or until expired on 31 December 2024 (whichever is earlier). Further request in writing will be required if 3. Shareholder prefers to continue receiving printed copy of future Corporate Communications.

此請求將一直有效,除非被撤銷或取代,或者直到 2024年 12 月 31 日到期(以較早者為準)。如果股東希室繼續收到日後的公司通訊的印刷本,則需要做 進一步書面請求。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

"Personal Data" in this statement has the same meaning as "personal data" defined in the Personal Data (Privacy) Ordinance, Cap. 486 (the "PDPO"), which may include but not limited to your name, contact telephone number, email address and mailing address.

Your supply of Personal Data is on a voluntary basis for the purpose of receiving Corporate Communications in the manner chosen. Your Personal Data will be retained for such period as may be necessary for our verification and record purposes. You have the right to request access to and/or to correct the respective Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction

of the Personal Data should be in writing by either of the following means: 本聲明中所指的「個人資料」具有香港法例第 486 章《個人資料(私隱)條例》(「《私隱條例》」)中「個人資料」的涵義,包括但不限於, 閣下的名稱,聯

絡電話號碼,電子郵箱地址和郵寄地址。

閣下是自願向本公司提供 閣下個人資料,以便以 閣下所選之方式接收企業通訊。 閣下的個人資料將在適當期間保留作核實及記錄用途。

閣下有權根據《私隱條例》的條文要求查閱及/或修改 閣下的個人資料。任何該等要求均須以書面方式提出。

By mail to: Data Privacy Officer Tricor Investor Services Limited

17/F. Far East Finance Centre 16 Harcourt Road, Hong Kong By email to: <u>is-enquiries@hk.tricorglobal.com</u> 經郵寄: 個人資料私隱主任 卓佳證券登記有限公司 香港夏慤道 16號

遠東金融中心 17 樓 經雷郵: is-enquiries@hk.tricorglobal.com

Please cut the mailing label and stick it on an envelope to return this Request Form to us. No postage is necessary if posted in Hong Kong.

閣下寄回本申請表格時,請將郵寄標籤剪貼於信封上。

如在本港投寄, 閣下無需支付郵費或貼上郵票。

Mailing Label 郵寄標籤

Tricor Investor Services Limited 卓佳證券登記有限公司 Freepost No. 簡便回郵號碼:10 GPO Hong Kong 香港 **Ascentage Pharma Group International** 亞盛醫藥集團 (6855)